Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

ErbB3, a member of the ErbB family of receptor tyrosine kinases, is a potent activator of phosphatidyl inositol-3 kinase (PI3K) and mTOR signaling, driving tumor cell survival and therapeutic resistance in breast cancers. In luminal breast cancers, ErbB3 upregulation following treatment with the ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Morrison, Meghan M., Williams, Michelle M., Vaught, David B., Hicks, Donna, Lim, Jiyeon, McKernan, Courtney, Aurisicchio, Luigi, Cennaro, Gilberto, Simion, Catalina, Sweeney, Colleen, Cook, Rebecca S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703573/
https://www.ncbi.nlm.nih.gov/pubmed/26148232
http://dx.doi.org/10.1038/onc.2015.169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703573/
https://www.ncbi.nlm.nih.gov/pubmed/26148232
http://dx.doi.org/10.1038/onc.2015.169

Ejemplares similares